In the recent announcement, Neuren highlighted that the U.S. Patent and Trademark Office has issued a Notice of Allowance for two new patents. One for NNZ-2566 and the second for NNZ-2591;
Seven patents for composition, methods of use and formulation have previously been issued for NNZ-2566 and three patents for composition and methods of use have been issued for NNZ-2591.
Which means we are still waiting for six more for NNZ-2566 and two more for NNZ-2591.
This will further enhance the commercial value of Neuren's drug pipeline as highlighted in announcement by CEO, Larry Glass.
Tony
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$16.48 |
Change
-0.290(1.73%) |
Mkt cap ! $2.076B | |||
| Open | High | Low | Value | Volume |
| $16.58 | $16.74 | $16.40 | $9.107M | 549.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 864 | $16.43 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.50 | 1668 | 1 |
View Market Depth
| Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
| NEU (ASX) Chart |